Reuters logo
BRIEF-Cyclacel reports top-line results from phase 3 study in patients with acute myeloid leukemia
February 23, 2017 / 12:12 PM / 7 months ago

BRIEF-Cyclacel reports top-line results from phase 3 study in patients with acute myeloid leukemia

Feb 23 (Reuters) - Cyclacel Pharmaceuticals Inc

* Cyclacel announces top-line results from pivotal phase 3 seamless study in elderly patients with acute myeloid leukemia

* Cyclacel Pharmaceuticals Inc - study did not reach statistically significant improvement in primary endpoint of overall survival

* Cyclacel Pharmaceuticals Inc - improvement in secondary endpoint of complete remission rate for experimental arm

* Cyclacel Pharmaceuticals Inc says cash resources are projected to fund these activities and operations through end of 2018

* Cyclacel Pharmaceuticals Inc - cash resources are projected to fund these activities and operations through end of 2018

* Cyclacel Pharmaceuticals-plan to discuss data from seamless with european, us regulators once subgroup analyses are completed in next few months Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below